Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RIVASTIGMINE vs ROACTEMRA: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RIVASTIGMINE vs ROACTEMRA: Safety Overview

Metric RIVASTIGMINE ROACTEMRA
Total FAERS Reports 9,123 164
Deaths Reported 2,232 14
Death Rate 24.5% 8.5%
Hospitalizations 2,716 65
Average Patient Age 80.0 yrs 51.2 yrs
% Female Patients 59.5% N/A
FDA Approval Date Apr 21, 2000 N/A
Manufacturer Novartis Pharmaceuticals Corporation N/A
Route TRANSDERMAL N/A
Marketing Status Discontinued N/A